RubenNiesvizkyMD

Hematologic Oncology

Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Niesvizky

Dr. Ruben Niesvizky is a hematologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, and NewYork-Presbyterian/Columbia University Irving Medical Center. He received his medical degree from Universidad Nacional Autonoma de Mexico and has been in practice 32 years. Dr. Niesvizky accepts several types of health insurance, listed below. He is one of 64 doctors at New York-Presbyterian Hospital and one of 25 doctors at NewYork-Presbyterian/Columbia University Irving Medical Center who specialize in Hematology. He also speaks multiple languages, including Hebrew and Spanish. He has more than 100 publications and over 500 citings.

Office
425 E 61st St
Fl 8
New York, NY 10065
Book by Phone+1(315) 683-4162

Fax+1 212-746-8961

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1990 - 1994
Icahn School of Medicine at Mount SinaiFellowship, Hematology and Medical Oncology, 1988 - 1990
Universidad Nacional Autonoma de MexicoClass of 1985

Certifications & Licensure

OR State Medical License 1993 - Present
NY State Medical License 1994 - 2025

Awards, Honors, & Recognition

Top doctors Newsweek, 2015
New York Magazine: Top Doctors Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma Start of enrollment: 2005 Jun 01
Completed
Phase 2
Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma Start of enrollment: 2004 Dec 01
Completed
Phase 2
Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Start of enrollment: 2007 Oct 01
Completed
Phase 2
Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma Start of enrollment: 2007 Dec 01
Terminated
Phase 2
Conditioning Regimen of Bendamustine and Melphalan Followed by Transplant in Patients With Multiple Myeloma Start of enrollment: 2009 Apr 23
Completed
Phase 1, Phase 2
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma Start of enrollment: 2010 Jun 01
Completed
Phase 3
Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma Start of enrollment: 2011 Mar 01
Completed
Phase 3
Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma Start of enrollment: 2010 Aug 01
Completed
Phase 2
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma Start of enrollment: 2012 Mar 01
Active, not recruiting
Phase 2
Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma Start of enrollment: 2013 Jul 08
Completed
Phase 3
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma Start of enrollment: 2014 Feb 01
Terminated
Phase 1
Study of ACY-241 Alone and in Combination With Pomalidomide and Dexamethasone in Multiple Myeloma Start of enrollment: 2015 May 07
Active, not recruiting
Phase 1
A Safety Study of SGN-CD352A for Patients With Relapsed/Refractory Multiple Myeloma Start of enrollment: 2016 Dec 01
Terminated
Phase 1
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22
Completed
Phase 1
A Safety Study of SEA-BCMA in Patients With Multiple Myeloma Start of enrollment: 2018 Nov 01
Terminated
Phase 1
A Study of the Safety, Tolerability and Effectiveness of EZM0414 Investigative Product in Participants With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma Start of enrollment: 2021 Nov 11
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Phase 1/2 Study of ISB 1442 in Relapsed/Refractory Multiple Myeloma Start of enrollment: 2022 Sep 27
Recruiting
Phase 1, Phase 2
Roles: Contact
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Active, not recruiting
Phase 1
Roles: Principal Investigator
Join now to see all

Publications & Presentations

PubMed

5 citations
Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
Sheri Skerget, Daniel Penaherrera, Ajai Chari, Sundar Jagannath, David S Siegel
Nature Genetics. 2024-09-01
1 citations
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma.
Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H Mouhieddine, Juan Esteban Velez-Hernandez
Blood Advances. 2024-08-13
Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM-3 study.
Michael H Tomasson, Shinsuke Iida, Ruben Niesvizky, Mohamad Mohty, Nizar J Bahlis
Hemasphere. 2024-07-01

Journal Articles

Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVOR
Ruben Niesvizky, David Siegel, Ralph Boccia, Blood

Abstracts/Posters

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)
Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Similar Survival with Deferred Versus Salvage Autologous Stem Cell Transplant in Light Chain Amyloidosis
Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not ...
Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Inferior Survival with Use of Autologous Stem Cell Transplant As Second-Line Therapy in Multiple Myeloma
Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Harnessing the Epichaperome As a Therapeutic Approach in Multiple Myeloma
Ruben Niesvizky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

Hematogenous Extramedullary Relapse in Multiple Myeloma - A Multicenter Retrospective Study in 127 Patients
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Blood Test May Guide Multiple Myeloma Immunotherapy UseJuly 27th, 2024
Routine Blood Test May Guide Use of Multiple Myeloma ImmunotherapyJuly 24th, 2024
A Day in the Life of a Nurse Who Works 10-Hour Shifts in an NYC Cancer Unit Keeping Patients Comfortable in the Midst of a National Drug ShortageAugust 21st, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American Society of Hematology - ASH
Member

Other Languages

Hebrew, Spanish

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
HIP of New York - Select PPO
MagnaCare PPO
MVP Healthcare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment